1. Home
  2. VRTS vs DBVT Comparison

VRTS vs DBVT Comparison

Compare VRTS & DBVT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Virtus Investment Partners Inc.

VRTS

Virtus Investment Partners Inc.

HOLD

Current Price

$147.61

Market Cap

1.1B

Sector

Finance

ML Signal

HOLD

DBVT

DBV Technologies S.A.

HOLD

Current Price

$21.41

Market Cap

1.1B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
VRTS
DBVT
Founded
1988
2002
Country
United States
France
Employees
N/A
90
Industry
Investment Managers
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.1B
1.1B
IPO Year
1995
2014

Fundamental Metrics

Financial Performance
Metric
VRTS
DBVT
Price
$147.61
$21.41
Analyst Decision
Hold
Buy
Analyst Count
5
7
Target Price
$171.60
$31.75
AVG Volume (30 Days)
74.6K
373.8K
Earning Date
05-08-2026
01-01-0001
Dividend Yield
6.55%
N/A
EPS Growth
N/A
N/A
EPS
14.81
N/A
Revenue
N/A
$4,151,000.00
Revenue This Year
N/A
$1,768.71
Revenue Next Year
$2.58
$1,028.88
P/E Ratio
$9.92
N/A
Revenue Growth
N/A
N/A
52 Week Low
$134.81
$3.82
52 Week High
$214.88
$26.19

Technical Indicators

Market Signals
Indicator
VRTS
DBVT
Relative Strength Index (RSI) 40.92 52.25
Support Level $135.70 $19.96
Resistance Level $148.22 $24.65
Average True Range (ATR) 6.34 1.39
MACD -0.05 -0.31
Stochastic Oscillator 32.11 35.00

Price Performance

Historical Comparison
VRTS
DBVT

About VRTS Virtus Investment Partners Inc.

Virtus Investment Partners Inc provides investment management and related services to institutions and individuals. It uses a multi-manager, multi-style approach, offering investment strategies from investment managers, each having its distinct investment style, autonomous investment process, and individual brand, as well as from select unaffiliated managers for certain funds. Through its multi-manager model, the group provides investment managers with distribution, business, and operational support. The Company operates in one business segment, namely as an asset manager providing investment management and related services for individual and institutional clients.

About DBVT DBV Technologies S.A.

DBV Technologies SA is a clinical-stage specialty biopharmaceutical company focused on changing the field of immunotherapy by developing a novel technology platform called Viaskin. The therapeutic approach is based on epicutaneous immunotherapy or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin, an epicutaneous patch (i.e., a skin patch). Its main product candidate under development is Viaskin Peanut for the treatment of peanut-allergic patients. In addition, the company also has earlier-stage food allergy programs, including Viaskin Milk and Eosinophilic Esophagitis, or EoE.

Share on Social Networks: